Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Journal:

The New England Journal of Medicine

Published:

2026-01-22

DOI:

10.1056/nejmoa2508959

Affiliations:

19

Authors:

20

Go to article

Institutions	Authors	Share
Gilead, United States of America (USA)	4.000000	0.20
Seoul National University Hospital (SNUH), South Korea	1.000000	0.05
Institute Gustave-Roussy (IGR), France	1.000000	0.05
Virgen del Rocío University Hospital, Spain	1.000000	0.05
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.05
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.05
SCIENTIA Investigación Clínica, Mexico	1.000000	0.05
Juntendo University, Japan	1.000000	0.05
Hospital de Câncer Araújo Jorge, Brazil	1.000000	0.05
Institute Jules Bordet, ULB, Belgium	1.000000	0.05
Asan Medical Center (AMC), South Korea	1.000000	0.05
AdventHealth, United States of America (USA)	1.000000	0.05
The Winship Cancer Institute of Emory University, United States of America (USA)	1.000000	0.05
Queen Mary University of London (QMUL), United Kingdom (UK)	1.000000	0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia	0.500000	0.03
The University of Melbourne (UniMelb), Australia	0.500000	0.03
University of Pretoria (UP), South Africa	0.500000	0.03
The Medical Oncology Centre of Rosebank, South Africa	0.500000	0.03

Interested in Oncology and Carcinogenesis?